Research Reports Coverage on Select Healthcare Stocks -- ZELTIQ Aesthetics, Globus Medical, Align Technology, and Nxstage Medical

Sep 22, 2016, 07:45 ET from Chelmsford Park SA

NEW YORK, September 22, 2016 /PRNewswire/ --

On Wednesday, September 21, 2016, the NASDAQ Composite ended the trading session at 5,295.18, up 1.03%; the Dow Jones Industrial Average edged 0.90% higher, to finish at 18,293.70; and the S&P 500 closed at 2,163.12, up 1.09%. The gains were broad based as all the sectors ended the session in positive. initiated research reports on the following Healthacre equities: ZELTIQ Aesthetics Inc. (NASDAQ: ZLTQ), Globus Medical Inc. (NYSE: GMED), Align Technology Inc. (NASDAQ: ALGN), and Nxstage Medical Inc. (NASDAQ: NXTM). Learn more about these stocks by downloading their comprehensive and free reports at:

ZELTIQ Aesthetics  

Pleasanton, California headquartered ZELTIQ Aesthetics Inc.'s stock edged 0.92% higher, to close the day at $39.33. The stock recorded a trading volume of 948,159 shares, which was above its three months average volume of 758,800 shares. ZELTIQ Aesthetics' shares have gained 4.32% in the last one month, 45.50% in the previous three months, and 11.48% in the past one year. Shares of the Company, which engages in developing and commercializing non-invasive products for the selective reduction of fat, are trading 9.30% and 36.49% above its 50-day and 200-day moving averages, respectively. Additionally, the stock traded at a PE ratio of 58.97 and has a Relative Strength Index (RSI) of 60.53.

Yesterday, research firm Stifel reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $38 a share to $52 a share. ZLTQ complete research report is just a click away and free at:

Globus Medical  

Shares in Audubon, Pennsylvania headquartered Globus Medical Inc. ended Wednesday's session 1.13% higher at $22.46 with a total volume of 376,669 shares traded. The stock is trading 4.55% below its 50-day moving average and 7.67% below its 200-day moving average. Moreover, shares of the Company, which focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders, traded at a PE ratio of 18.33 and have an RSI of 40.59. The complimentary report on GMED can be downloaded at:

Align Technology  

On Wednesday, shares in San Jose, California headquartered Align Technology Inc. recorded a trading volume of 1.33 million shares, which was higher than their three months average volume of 713,530 shares. The stock ended the day 1.75% higher at $95.34. Shares of the Company, which designs, manufactures, and markets a system of clear aligner therapy, intra-oral scanners, and computer-aided design and computer-aided manufacturing (CAD/CAM) digital services for use in dentistry, orthodontics, and dental records storage in the US and internationally, traded at a PE ratio of 46.35. Align Technology Inc.'s stock has gained 1.00% in the last one month, 18.55% in the previous three months and 67.65% in the past one year. The Company is trading above its 50-day and 200-day moving averages by 4.97% and 25.72%, respectively. Furthermore, shares of Align Technology have an RSI of 60.96. Sign up for your complimentary research report on ALGN at:

Nxstage Medical  

Lawrence, Massachusetts headquartered Nxstage Medical Inc.'s stock finished Wednesday's session 2.44% higher at $24.80 with a total volume of 230,880 shares traded. Over the last one month and the previous three months, Nxstage Medical's shares have gained 4.47% and 27.97%, respectively. Further, the stock has surged 45.37% in the past one year. Shares of the Company, which develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure, are trading above its 50-day and 200-day moving averages by 6.79% and 28.90%, respectively. Nxstage Medical's stock has an RSI of 65.76. Get free access to your research report on NXTM at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:  +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA